SiBone (NASDAQ:SIBN) Director Mika Nishimura Sells 4,100 Shares

SiBone (NASDAQ:SIBN) Director Mika Nishimura sold 4,100 shares of the business’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $13.83, for a total transaction of $56,703.00. Following the completion of the transaction, the director directly owned 32,716 shares of the company’s stock, valued at $452,462.28. This trade represents a 11.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

SiBone Trading Down 5.6%

SiBone stock traded down $0.77 during mid-day trading on Friday, hitting $13.05. 853,615 shares of the company’s stock were exchanged, compared to its average volume of 583,311. The company’s 50 day simple moving average is $16.28 and its 200-day simple moving average is $16.72. The company has a quick ratio of 7.21, a current ratio of 8.55 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $576.42 million, a P/E ratio of -29.66 and a beta of 0.69. SiBone has a fifty-two week low of $12.49 and a fifty-two week high of $21.89.

SiBone (NASDAQ:SIBN) last posted its earnings results on Monday, February 23rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.09. The firm had revenue of $56.35 million during the quarter, compared to analysts’ expectations of $56.26 million. SiBone had a negative return on equity of 11.01% and a negative net margin of 9.41%. On average, equities analysts anticipate that SiBone will post -0.78 earnings per share for the current year.

Institutional Trading of SiBone

Hedge funds and other institutional investors have recently made changes to their positions in the business. Royal Bank of Canada boosted its holdings in SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after purchasing an additional 736 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in SiBone by 0.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 225,001 shares of the company’s stock valued at $4,437,000 after buying an additional 997 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in SiBone by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after buying an additional 1,053 shares during the last quarter. Larson Financial Group LLC lifted its position in SiBone by 42.3% during the 4th quarter. Larson Financial Group LLC now owns 3,569 shares of the company’s stock worth $70,000 after buying an additional 1,061 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of SiBone by 4.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,159 shares of the company’s stock worth $733,000 after buying an additional 1,459 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SIBN has been the topic of a number of research reports. Needham & Company LLC lifted their price target on shares of SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. TD Cowen increased their price objective on shares of SiBone from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Morgan Stanley boosted their price objective on shares of SiBone from $20.00 to $23.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Canaccord Genuity Group upped their target price on shares of SiBone from $26.00 to $27.00 and gave the stock a “buy” rating in a research note on Wednesday, December 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $24.67.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.